# PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

> **NCT07549958** · PHASE1 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 18 (estimated)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** Pitavastatin

## Key facts

- **NCT ID:** NCT07549958
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549958, "PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07549958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*